Concert Pharmaceuticals, Inc. (CNCE)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Concert Pharmaceuticals, Inc. (CNCE) trades at $8.37 with AI Score 46/100 (Grade C). Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative small molecule drugs for autoimmune diseases. Sector: Healthcare.
Last analyzed: May 10, 2026Analyst Coverage for CNCE: CNCE does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CNCE against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CNCE: the 1 perspectives are evenly split.
Concert Pharmaceuticals, Inc. (CNCE) Healthcare & Pipeline Overview
Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in novel small molecule drugs aimed at treating autoimmune diseases, with a strong focus on alopecia areata through its lead candidate, CTP-543, currently in advanced clinical trials.
What Is the Investment Thesis for CNCE?
Concert Pharmaceuticals, Inc. is positioned for significant growth driven by its lead product candidate, CTP-543, which is in Phase III clinical trials for alopecia areata. The successful completion of these trials could lead to potential FDA approval, providing a substantial revenue stream in a market estimated to be worth over $2 billion. Additionally, strategic partnerships with established pharmaceutical companies enhance its research capabilities and market access, further solidifying its competitive position. The company’s focus on innovative small molecule drugs for autoimmune diseases taps into a growing market, as the prevalence of such conditions continues to rise. However, the company faces risks associated with clinical trial outcomes and regulatory approvals, which could impact its financial performance. Overall, the combination of a robust pipeline, strategic collaborations, and a focus on high-demand therapeutic areas positions Concert Pharmaceuticals for potential long-term success.
Based on FMP financials and quantitative analysis
CNCE Key Highlights
- Lead product candidate CTP-543 in Phase III trials for alopecia areata, targeting a market worth over $2 billion.
- Gross margin of 100%, indicating strong product potential and pricing power.
- Strategic collaborations with major pharmaceutical companies enhance research and development capabilities.
- Lean operational structure with 64 employees, focusing on efficiency and innovation.
- No dividend yield, reflecting a reinvestment strategy aimed at long-term growth.
Who Are CNCE's Competitors?
CNCE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals plc | $231.29 | -2.07% | $14.51B | 58 |
| PCSA Processa Pharmaceuticals, Inc. | $2.36 | -0.42% | $5.35M | — |
| SNDX Syndax Pharmaceuticals, Inc. | $18.02 | +0.61% | $1.60B | 79 |
| ANAB AnaptysBio, Inc. | $56.07 | +3.37% | 3B | 79 |
| ABCL AbCellera Biologics Inc. | $5.23 | -0.76% | $1.60B | 76 |
| CGEN Compugen Ltd. | $2.02 | -0.98% | $191.00M | 76 |
| NWPHF Newron Pharmaceuticals S.p.A. | $20.00 | +0.00% | $416.12M | 68 |
| CELU Celularity Inc. | $0.73 | +0.44% | $17.56M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CNCE's Key Strengths?
- Innovative product pipeline with focus on autoimmune diseases.
- Strong partnerships with established pharmaceutical companies.
- Robust clinical trial framework and experienced management team.
What Are CNCE's Weaknesses?
- Currently in clinical stages with no approved products on the market.
- High dependency on successful trial outcomes for financial stability.
- Limited operational scale with only 64 employees.
What Could Drive CNCE Stock Higher?
- Completion of Phase III clinical trials for CTP-543, expected within the next 12-18 months.
- Strategic collaborations with major pharmaceutical companies to enhance research and development efforts.
- Potential FDA submission for CTP-543 following successful trial outcomes.
What Are the Key Risks for CNCE?
- Regulatory challenges that may delay or hinder drug approvals.
- Dependence on the success of clinical trials for financial stability.
- Competition from other biotechnology firms developing similar treatments.
What Are the Growth Opportunities for CNCE?
- CTP-543 Approval: The Phase III trials for CTP-543 are a critical milestone, with potential FDA approval expected in the next 12-18 months. Success could unlock a market estimated at over $2 billion, providing a substantial revenue opportunity for Concert Pharmaceuticals.
- Expansion of Pipeline: Concert Pharmaceuticals is actively exploring additional indications for CTP-543 and other drug candidates targeting different autoimmune diseases. This pipeline expansion could diversify revenue streams and mitigate risks associated with reliance on a single product.
- Strategic Partnerships: Ongoing collaborations with established pharmaceutical companies such as Jazz Pharmaceuticals and Avanir Pharmaceuticals may facilitate faster development timelines and broader market access. These partnerships can enhance resource allocation and provide additional funding for research initiatives.
- Market Demand for Autoimmune Treatments: The increasing prevalence of autoimmune diseases presents a growing market opportunity. As awareness and diagnosis rates rise, Concert Pharmaceuticals stands to benefit from the heightened demand for effective treatments in this therapeutic area.
- Innovative Drug Development: Concert's focus on novel small molecule drugs positions it favorably within the biotechnology sector. The ability to develop targeted therapies that address specific autoimmune conditions can lead to competitive advantages and increased market share.
What Opportunities Does CNCE Have?
- Growing market for autoimmune disease treatments.
- Potential for pipeline expansion into additional therapeutic areas.
- Increased collaboration opportunities within the biotechnology sector.
What Threats Does CNCE Face?
- Regulatory hurdles and uncertainties surrounding drug approvals.
- Intense competition from other biotechnology firms.
- Market volatility affecting funding and investment.
What Are CNCE's Competitive Advantages?
- Strong focus on innovative drug development differentiates Concert from competitors.
- Strategic partnerships enhance research capabilities and market access.
- Robust clinical trial pipeline reduces time to market for new therapies.
What Does CNCE Do?
Founded in 2006 and headquartered in Lexington, Massachusetts, Concert Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company dedicated to developing innovative small molecule drugs for the treatment of autoimmune diseases. The company has carved a niche in the biotechnology sector by focusing on conditions that are often overlooked, such as alopecia areata, a serious autoimmune dermatological condition. Concert's lead product candidate, CTP-543, is currently undergoing Phase III clinical trials, representing a significant milestone in its development pipeline. The company has established strategic collaborations with notable firms such as Avanir Pharmaceuticals, Inc., Jazz Pharmaceuticals, Inc., Cipla Technologies, and Processa Pharmaceuticals, which enhance its research capabilities and market reach. These partnerships are critical for accelerating the development and commercialization of its product candidates. As of now, Concert Pharmaceuticals employs 64 individuals, showcasing a lean operational structure that emphasizes efficiency and innovation. The company's commitment to addressing unmet medical needs positions it favorably within the competitive landscape of biotechnology, where rapid advancements and breakthroughs are commonplace. With a gross margin of 100% and no dividend yield, Concert Pharmaceuticals is focused on reinvesting its resources into research and development to drive future growth.
What Products and Services Does CNCE Offer?
- Develop novel small molecule drugs for autoimmune diseases.
- Conduct clinical trials to evaluate the safety and efficacy of drug candidates.
- Collaborate with other pharmaceutical companies for research and development.
- Focus on unmet medical needs in the autoimmune disease space.
- Utilize innovative drug development technologies to enhance product offerings.
- Aim to bring effective treatments to market for conditions like alopecia areata.
How Does CNCE Make Money?
- Generate revenue through the successful commercialization of drug candidates.
- Engage in strategic partnerships to share research and development costs.
- Focus on clinical trials to validate drug efficacy and safety.
- Leverage intellectual property to protect innovations and secure market position.
What Industry Does CNCE Operate In?
The biotechnology industry is experiencing rapid growth, driven by advancements in drug development technologies and an increasing focus on personalized medicine. The global autoimmune disease treatment market is projected to expand significantly, with a compound annual growth rate (CAGR) of approximately 8% over the next several years. Concert Pharmaceuticals, with its specialized focus on autoimmune conditions, is well-positioned to capitalize on these trends. The competitive landscape includes various players, but Concert's unique approach to developing small molecule drugs offers a differentiated strategy in a crowded market.
Who Are CNCE's Key Customers?
- Healthcare providers seeking effective treatments for autoimmune diseases.
- Patients suffering from conditions like alopecia areata.
- Pharmaceutical partners involved in collaborative research and development.
CNCE Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's growth trajectory, indicating a belief in upcoming positive developments.
- Community sentiment has shifted positively, with many discussions highlighting the potential of their pipeline and recent clinical advancements.
- The market is reacting favorably to recent partnerships, which may enhance their research capabilities and market reach.
- Increased media coverage has raised awareness of Concert Pharmaceuticals, attracting more retail investors who are optimistic about future prospects.
Bear Case
- Concerns persist regarding the competitive landscape, as several competitors are advancing similar therapies, which could dilute market share.
- Recent clinical trial results have raised questions about efficacy, leading to skepticism among some investors in the community.
- Negative sentiment has emerged from some analysts who question the sustainability of the company's business model without consistent revenue streams.
- Overall market volatility has created a cautious atmosphere, with some investors wary of speculative plays in the biotech sector.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CNCE Latest News
-
74 Biggest Movers From Yesterday
benzinga · Jun 3, 2022
-
53 Stocks Moving In Thursday's Mid-Day Session
benzinga · Jun 2, 2022
-
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
· Nov 9, 2021
-
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
· Sep 15, 2021
CNCE Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CNCE.
Price Targets
Wall Street price target analysis for CNCE.
CNCE MoonshotScore
What does this score mean?
The MoonshotScore rates CNCE's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
74 Biggest Movers From Yesterday
53 Stocks Moving In Thursday's Mid-Day Session
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
Leadership: Roger D. Tung
CEO
Roger D. Tung has extensive experience in the biopharmaceutical industry, having held various leadership positions throughout his career. He co-founded Concert Pharmaceuticals and has been instrumental in shaping its strategic direction. Tung holds a degree in chemistry from Harvard University and an M.D. from the University of Pennsylvania, providing him with a strong foundation in both science and medicine.
Track Record: Under Roger D. Tung's leadership, Concert Pharmaceuticals has successfully advanced its lead candidate CTP-543 into Phase III trials. His strategic vision has fostered key partnerships and collaborations that enhance the company's research capabilities and market position.
Concert Pharmaceuticals, Inc. Healthcare Stock: Key Questions Answered
What does Concert Pharmaceuticals, Inc. do?
Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative small molecule drugs for the treatment of autoimmune diseases. Its lead candidate, CTP-543, is currently in Phase III clinical trials targeting alopecia areata, and the company is committed to addressing unmet medical needs in this therapeutic area.
What do analysts say about CNCE stock?
Analysts generally view Concert Pharmaceuticals, Inc. as a high-risk, high-reward investment due to its clinical-stage status and reliance on successful trial outcomes. Key valuation metrics include its current market capitalization and projected revenue from CTP-543, should it receive FDA approval. Analysts emphasize the importance of upcoming clinical trial results in shaping future stock performance.
What are the main risks for CNCE?
Concert Pharmaceuticals, Inc. faces several risks, including regulatory hurdles that could impede the approval of its lead product candidate, CTP-543. Additionally, the company's financial stability is heavily reliant on the success of clinical trials, which are inherently uncertain. The competitive landscape in the biotechnology sector also poses a threat, as other firms may develop similar or superior treatments.
What are the key factors to evaluate for CNCE?
Concert Pharmaceuticals, Inc. (CNCE) holds an AI score of 46/100 (low). Not financial advice.
How frequently does CNCE data refresh on this page?
CNCE prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CNCE's recent stock price performance?
Concert Pharmaceuticals, Inc. (CNCE) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product pipeline with focus on autoimmune diseases. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CNCE overvalued or undervalued right now?
Valuing Concert Pharmaceuticals, Inc. (CNCE) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CNCE?
Before investing in Concert Pharmaceuticals, Inc. (CNCE), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The information provided is based on available data and may be subject to change as new developments occur.